Sun et al. demonstrated that tissue or circulating tumor DNA PTPRD mutation is a prognostic biomarker predicting prognosis of anti-PD-(L)1 monotherapy in non-squamous NSCLC patients [41]. The gene discussed is PTPRD; the disease is neoplasm.